Summary
McKesson Corporation reported its third-quarter and nine-month results for the period ending December 31, 2010. For the third quarter, revenues remained stable year-over-year at $28.2 billion, while net income saw a significant decrease of 52% to $155 million, leading to diluted EPS of $0.60. This decline was largely impacted by a substantial $189 million pre-tax charge related to Average Wholesale Price (AWP) litigation, increased acquisition costs for the US Oncology acquisition, and a decrease in demand due to the H1N1 flu virus. For the nine-month period, revenues increased by 1% to $83.2 billion, but net income decreased by 15% to $780 million, with diluted EPS at $2.96. The nine-month results were also affected by AWP litigation charges and an asset impairment charge on capitalized software, though partially offset by a gain from the sale of a subsidiary and an antitrust settlement. The company completed the significant acquisition of US Oncology for approximately $2.1 billion, which expands its specialty pharmaceutical distribution business and adds practice management services.
Financial Highlights
48 data points| Revenue | $28.25B |
| Cost of Revenue | $26.79B |
| Gross Profit | $1.46B |
| Operating Expenses | $1.15B |
| Operating Income | $307.00M |
| Net Income | $155.00M |
| EPS (Basic) | $0.61 |
| EPS (Diluted) | $0.60 |
| Shares Outstanding (Basic) | 254.00M |
| Shares Outstanding (Diluted) | 258.00M |
Key Highlights
- 1Revenues for the third quarter ended December 31, 2010, remained stable at $28.2 billion compared to the prior year quarter.
- 2Net income for the third quarter decreased by 52% to $155 million, resulting in diluted EPS of $0.60, significantly impacted by a $189 million AWP litigation charge.
- 3The company completed a major acquisition of US Oncology for approximately $2.1 billion, expanding its oncology services and practice management offerings.
- 4For the nine months ended December 31, 2010, revenues increased 1% to $83.2 billion, while net income decreased 15% to $780 million ($2.96 diluted EPS).
- 5Operating expenses increased substantially in the quarter due to the AWP litigation charge and acquisition costs related to US Oncology.
- 6The Distribution Solutions segment, which represents the majority of revenue, saw a decrease in operating profit margin, primarily due to litigation charges and a decline in demand related to H1N1.
- 7McKesson declared a quarterly dividend of $0.18 per common share, an increase from the previous year's $0.12.